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Abstract 
Advances in the management of non-small cell lung cancer (NSCLC) over the past 30 years have led 
to small increases in 5-year survival rates across Europe, though further improvements may require 
new treatment strategies. In order to improve efficiency and reduce the cost of development, future 
trials for new targeted agents in NSCLC should aim to recruit patients on the basis of tumour biology 
rather than clinical characteristics. However, identification of predictive biomarkers is required to 
maximise the benefits of new approaches and expedite the drug development process. 
Nevertheless, the NSCLC landscape is changing rapidly, and recent improvements in our
understanding of the molecular biology of the disease will help in the identification of novel targeted 
agents as well as assisting in the development of personalised strategies for the numerous small 
subsets of defined NSCLC. Progress in imaging and treatment delivery is also likely to improve 
outcomes for patients with the disease. This article outlines recent progress in the treatment of 
NSCLC, identifies current challenges and describes proposals for improving the future management 
of the disease. It is hoped that implementation of some of these strategies will go some way to 
improving the outlook for patients with NSCLC.
KEYWORDS: Biomarkers, Clinical trials, Lung cancer, Management, Molecular profiling, Outcomes, 
Pathogenesis, Treatment
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Introduction
Despite advances in the understanding of tumour biology in recent years, lung cancer mortality in 
Europe has remained largely unchanged over the past three decades, underlying the need for new 
treatment strategies [1,2]. Earlier diagnosis is also important, since outcome is primarily related to 
stage at diagnosis, with 5-year survival rates being over 70% for those with stage I disease falling to 
less than 5% for stage IV. Further challenges for improving NSCLC outcome include integration of 
new advances in clinical, pathological and molecular aspects into the management of the condition, 
since the landscape is changing rapidly.
Molecular pathology of NSCLC 
Four main histological types of lung cancer are recognised: squamous cell carcinoma, 
adenocarcinoma and large cell carcinoma – known collectively as NSCLC – and small cell lung cancer 
(SCLC) [3,4]. However, mixed histology also occurs, complicating diagnostic evaluation. Nevertheless, 
the use of molecular analytical techniques in recent years has improved histological typing in lung 
cancer, especially in adenocarcinoma [3,5,6], with immunohistological markers such as cytokeratins 
(e.g. CK5/6) or transcription factors (e.g. p63, TTF1) being used to assist in the identification of 
different lung cancer subtypes in small biopsies where differentiation is not obvious. 
Recently, a new classification of lung adenocarcinomas has been proposed by the International 
Association for the Study of Lung Cancer, the American Thoracic Society and the European 
Respiratory Society (Table 1) [7]. The revised classification recognises that histological distinctions 
can be made between different prognostic subtypes, and that genetic alterations and response to 
therapy can be suggested by tumour pathology. It should be noted that diagnosis is made primarily 
on the basis of fine needle core biopsy or bronchial biopsies, limiting the amount of tissue available 
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for identifying different genetic alterations. Alternative biopsy methods should be considered, 
therefore, if molecular testing is planned. An algorithm, employing a minimal set of markers, is 
recommended for the diagnosis of lung cancer subtype in order to maximise the tumour tissue 
available for selected driver mutation research [7,8]. The new classification has been validated in a 
number of studies worldwide, including Europe [9,10]; however, its acceptance has been variable 
and more data may be required before it can be used to select patients for biomarker testing. 
Nevertheless, as new data emerge, the revised classification is expected to improve prognostic 
assessment for patients with adenocarcinoma, allowing subtyping to be used to stratify patients for 
treatment [10,11]. Recent studies characterising genomic alterations in NSCLC will also highlight new 
potential targets for treatment of the condition [12,13].
Use of biomarkers in NSCLC and the application of next-generation sequencing 
Predictive biomarkers are needed in NSCLC in order to maximise the benefits of new treatment 
strategies and expedite drug development. Ideally, biomarkers should be specific, adaptable for 
standard clinical use and present only in tumour tissue. A good understanding of the molecular 
biology of the target is also required for biomarker development due to the existence of multiple, 
inter-related signalling pathways. Biomarker studies are difficult to perform for a number of reasons, 
including regulatory issues and tumour heterogeneity, with markers for both poor and good 
prognosis being found in the same tumour [14,15]. Additionally, intellectual property rights for 
assays can be a barrier to the clinical implementation of biomarkers and may limit drug development 
for rare mutations (e.g. frequencies <1%). Consequently, for widespread clinical application, the 
development of inexpensive and reproducible assays in parallel with drug development (companion 
diagnostics) is required. Collaboration between centres is also needed in order to standardise 
biomarker analyses and limit false positive or negative outcomes. 
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A number of predictive biomarkers for NSCLC have already been introduced into clinical practice.
The most well established of these are epidermal growth factor receptor (EGFR) mutations and 
anaplastic lymphoma kinase (ALK) rearrangements, commonly in the form of the echinoderm 
microtubule-associated protein-like 4-anaplastic lymphoma kinase (EML4-ALK) fusion oncogene [16].
EGFR activating mutations are detectable in around 10% of patients with NSCLC in Western Europe
[17], the most common of which occur in exons 19–21 and confer sensitivity to the tyrosine kinase 
inhibitors (TKIs) erlotinib and gefitinib [18]. T790M, another frequently found EGFR mutation, is 
associated with TKI resistance and is present in around 50% of patients treated with EGFR TKIs at 
disease progression [19,20]. Recent data suggest that this mutation may be present at baseline 
rather than developing de novo after therapy [21]. EML4-ALK rearrangements are found in 2–7% of 
NSCLCs [22], most commonly in adenocarcinoma tumours from young people (<65 years old) who 
are light smokers or who have never smoked [23,24]. Other biomarkers thought to be associated 
with addiction to oncogenic driver mutations and that are predictive of response to specific agents in 
NSCLC include BRAF, HER2, ROS1, FGFR1 and MET. KRAS is a driver mutation for which no specific 
targeted drug has yet been identified, and is thought to confer relative resistance to EGFR TKIs [25–
32]. More evidence is required to validate biomarkers such as PIK3CA, ERCC1, MSH2, TS, BRCA1 and 
RRM1 [33,34].
Testing of adenocarcinomas for EGFR mutation and ALK rearrangement is now recommended in
current guidelines and is undertaken routinely in many centres [35]. The only validated assay for 
detecting ALK rearrangement at present is fluorescence in situ hybridisation (FISH), though good 
results have recently been achieved using an immunohistochemistry assay, which may be more 
applicable to routine testing [36]. DNA mutational analysis is the preferred method to assess EGFR
status [37–39]. As routine testing for increasing numbers of mutations is likely in the future, the 
quality and availability of tissue samples could well become an issue [40].
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One area that has seen an explosion in research in recent years is next-generation sequencing (NGS), 
which has the ability to fully sequence large numbers of genes in a single test (genome-wide 
analysis) with high sensitivity and at relatively low cost [41,42]. The genes identified can then be 
validated by re-sequencing, which can be used to help identify patients for particular treatments. A 
further important application for NGS in the future is the detection of mutations in body fluids, 
circulating tumour cells (CTCs), plasma or sera, since the mutations may be highly correlated with 
the primary tumour [43]. Sampling at different time points using this method may help to identify 
mutations evolving after different lines of treatment. NGS has already been adopted in some centres 
and may be used in the future to develop companion diagnostic tests for new drugs [44]. NGS holds 
great promise for the future, though the technology is not yet being used to guide treatment in 
NSCLC. Problems associated with the uptake of NGS include the lack of central regulation and 
standardisation for the platforms used, the interpretation and validation of findings, reimbursement 
and the financial implications of identifying rare mutations.  
Current treatment options and new developments for NSCLC in Europe 
Current treatment for NSCLC in Europe is based primarily on European Society for Medical Oncology 
(ESMO) guidelines [35], and is selected according to molecular subtype, performance status (PS) and 
comorbidity. However, local adaptations to treatment selection occur due to differing 
reimbursement policies and access to drugs. Furthermore, drug costs for long-term treatment are 
likely to play an increasingly important role in the future, particularly in the case of maintenance 
treatment for metastatic disease. 
The recommended first-line treatment for metastatic NSCLC is platinum-based chemotherapy for all 
patients with PS 0–2, with an EGFR TKI being given to those with tumours bearing an activating 
(sensitising) EGFR mutation [35,45]. For healthy patients with stage I–II NSCLC, lobectomy is the 
treatment of choice. Adjuvant cisplatin-based chemotherapy is recommended for patients with 
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stage II–III NSCLC after radical resection according to the 7th TNM (Tumour, Nodes, Metastasis) 
classification [46]. Current guidelines for patients with stage III disease recommend the use of 
chemotherapy and radiotherapy, either sequentially or (preferably) concurrently [46]. However, 
treatment for stage III NSCLC is particularly challenging due to patients’ comorbidities and tumour 
heterogeneity. Although treatment approaches for stage III NSCLC differ considerably between 
regions and centres, neoadjuvant (chemo-)radiotherapy followed by surgery remains a standard 
option in selected patients with resectable stage IIIA NSCLC. New drug development and research 
into the optimum chemo-radiation strategies for locally advanced NSCLC is also problematic due to 
the fact that patients are potentially curable and may not be willing to enrol in clinical trials. Novel 
approaches currently being investigated in stage III NSCLC include immunomodulatory strategies, 
agents acting on the cell cycle (e.g. aurora kinase inhibitors) and novel cytostatics [47,48]. ‘Window 
of opportunity’ trials undertaken before chemotherapy or chemo-radiotherapy may be a useful 
means of testing new agents or strategies in this population. Such trials allow the efficacy of novel 
therapies to be investigated before the development of resistance arising from prior therapy [49]. 
Although this approach raises possible ethical concerns relating to the use of an agent of 
indeterminate efficacy when standard therapies are available, window trials, if carefully controlled, 
can provide valuable information on the activity of new treatments for NSCLC [49,50]. 
The use of radiotherapy in lung cancer has seen a number of advances in recent years, with kinetics 
as well as heterogeneity of tumours being taken into account [51–53]. Uptake of radionuclides can 
also vary within tumours due to differing vascularisation. This presents the possibility of targeting 
different parts of the tumour with varying amounts of radiation to deliver higher doses with less 
toxicity [54]. Further possible future developments in radiotherapy are the combination of 
radiotherapy with targeted agents [55], and the use of proton-based technology, since such delivery 
improves target volume distribution and is more lung-sparing than photon-based delivery. Imaging 
biomarkers such as fluorodeoxyglucose (FDG)-positron emission tomography (PET) are also likely to 
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be used increasingly in the future to predict an early response to radiotherapy, with changes in FDG 
uptake by the primary tumour found to be significantly predictive for 2-year survival in stage III
NSCLC during the first week of (chemo-)radiotherapy [56].
Clinical challenges of drug resistance in advanced NSCLC 
Although cytotoxics like cisplatin have been used in the treatment of NSCLC for several decades, the 
mechanism(s) underlying resistance to these agents are poorly understood. Nevertheless, a number 
of predictive biomarkers for resistance to cytotoxics are being investigated, including ERCC1 and
RRM1. Data suggest that patients with low levels of RRM1 or ERCC1 expression may respond better 
to carboplatin/gemcitabine [57,58]. However, current data are not robust, particularly for ERCC1 
due to the lack of specificity of current antibodies [59]; prospective validation is needed, therefore,
before routine testing for ERCC1 or RRM1 can be recommended.
Mechanisms of resistance to TKIs include oncogene-dependent second-site mutations or gene 
amplification and oncogene-independent bypass tracks (Figure 1) [60]. Resistance also arises from 
tumour heterogeneity, since mutations are not found in every tumour cell and there could be 
outgrowth of subpopulations with rare mutations under treatment pressure, leading to acquired 
resistance [61]. In addition, resistance can occur as a result of pharmacokinetic factors due to 
decreases in drug levels, with differences occurring between patients; however, drug concentrations 
within tumours are not well understood.  
The T790M mutation is one of the major mechanisms of resistance to erlotinib and gefitinib [62]. 
The use of irreversible pan-HER agents (e.g. neratinib, afatinib) to overcome T790M EGFR resistance 
has not been encouraging, with very low response rates being observed [63,64]. Specific EGFR 
T790M inhibitors are also in development, though there are no clinical data with these agents to 
date [65]. The lack of success with targeting this mutation thus far may be due to the fact that its 
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expression is not well understood, and this highlights the need for caution when identifying 
resistance genes since they may not be activated in vivo. 
The optimum management for patients whose disease progresses after TKI therapy is unclear, and 
chemotherapy is the only approved systemic treatment at present. One strategy currently under 
investigation in this population is to continue TKI therapy beyond progression, using local treatment 
such as radiotherapy when needed, thus delaying a change in systemic therapy. Although there are 
no prospective data investigating TKI maintenance beyond progression, the results of retrospective 
studies suggest that this strategy may improve both response rate and survival [66,67].
A further approach for patients with TKI-resistant tumours is the combination of targeted agents. 
Indeed, the ongoing trial of cetuximab plus afatinib has demonstrated clinical benefit in 75% of 
patients with TKI-resistant NSCLC [68]. However, the use of a combination of targeted agents has 
been problematic to date due to toxicity. Consequently, the addition of a cytotoxic to a targeted 
agent may be a more promising strategy both in patients with TKI-resistant tumours [69] and
upfront in untreated patients [70].
Novel targets for drug treatment in NSCLC 
The biology of the different mutations in NSCLC is complex and validation of the various targets is 
challenging. Hundreds of new mutations have been identified in NSCLC in recent years, particularly 
non-hot spot mutations, which are present in 20–30% of NSCLC tumours, though establishing the 
relevance of these mutations is difficult. An improved understanding of these gene alterations is 
needed in order to assist in the identification of new therapeutic targets leading to improved clinical 
outcomes. This will require translational laboratory research to establish underlying oncogene 
addiction.
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Despite the complexity of the molecular biology of NSCLC, a vast array of new targets for NSCLC drug 
treatments are being investigated (Table 2), including HER2 and HER3. Although HER2 receptor 
overexpression occurs in around 30% of NSCLCs, the results of trials with anti-HER2 agents have not 
been encouraging [71,72]. As phosphorylation of EGFR is frequently through HER3 [73], addition of 
an anti-HER3 drug to improve the efficacy of anti-EGFR agents has also been investigated, and trials 
to investigate this strategy are ongoing. 
KRAS is a frequent mutation in lung cancer tumours that was previously thought to be un-druggable; 
however, recent studies suggest alternative ways of targeting this mutation. One such strategy 
involves inhibition of cyclin-dependent kinase 4 (CDK4), since KRAS appears to be dependent on this 
cell cycle progressing molecule in animal models [74]. Inhibition of MEK has also been investigated, 
with a progression-free survival (PFS) benefit being demonstrated for the MEK inhibitor, selumetinib, 
when used in combination with docetaxel in patients with KRAS mutant tumours [75]. The latter 
findings should be treated with caution, however, as the effects of this agent in KRAS wild-type or an 
unselected population is unknown. Nevertheless, recent preclinical data provide support for the 
combination of MEK and BCL-XL inhibition as a strategy for targeting KRAS [76]. Immunotherapeutic 
strategies are also being investigated, and encouraging results have been demonstrated for the anti-
cytotoxic T-cell lymphocyte-4 monoclonal antibody, ipilimumab, when used in combination with 
paclitaxel and carboplatin as first-line therapy in patients with stage III NSCLC [77]. Blockade of 
programmed death-1 (PD-1), a co-inhibitory receptor expressed by activated T-cells, has also been 
examined as a strategy to overcome immune resistance and mediate tumour regression [78], though 
selection of the subpopulation of patients who will benefit from this strategy will be challenging.
There is a need for improved trial designs for the development of new targeted agents for NSCLC, 
particularly when targeting rare and infrequent mutations like DNA repair deficiencies, with studies 
including assessment of biomarkers and involving selected populations. Ideally, new drugs should be 
Page 11 of 34
Ac
ce
pte
d M
an
us
cri
pt
11
investigated initially in the metastatic setting before earlier settings are studied, with development 
targeting the non-smoking population in the first instance to maximise response. 
Provision of healthcare services and treatment challenges for patients with NSCLC in 
Europe 
Improvements in the provision of oncology healthcare services in Europe are needed due to 
escalating drug costs and limited funds. While certain barriers to advances in healthcare provision 
exist in Europe (differences in language, local policies, medical approaches and funding), progress is 
being made, with a number of networks being set up to report on health status across the region. 
These networks (e.g. the European Oncology Thoracic Platform [ETOP], European Organization for 
the Research and Treatment of Cancer [EORTC] and the International Association for the Study of 
Lung Cancer [IASLC]) will play a key role in improving healthcare provision in oncology in the future, 
enabling collaboration between healthcare professionals and industry in order to improve outcomes
[79,80]. Such collaborations are important, since the incidence of lung cancer and mortality rates 
differ widely across Europe [1,81]. 
The advent of novel targeted therapy for patients with NSCLC has resulted in clear progress in the 
treatment of this common malignancy in recent years, though challenges still remain (Table 3). In 
particular, optimum use of novel agents requires the identification of predictive markers to 
determine the patients who will derive the most benefit. New models for clinical trials in NSCLC are 
also required, as the results of many Phase III trials with targeted agents undertaken over the last 
decade have been negative, primarily due to the inclusion of unselected patients and limited 
understanding of tumour biology [71,82–84]. The poor efficacy observed in early trials with targeted 
agents may also be due to cross-stimulation of the targets of these agents, such that interference 
with a single pathway may not be sufficient [85]. Consequently, to improve cure rates, consideration 
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should be given to the combination of targeted agents, with multiple biopsies being collected to 
study tumour evolution over time.
In order to improve efficiency and reduce the cost of development, future trials for new targeted 
agents in NSCLC should aim to recruit patients on the basis of tumour biology rather than clinical 
characteristics. Indeed the benefit of this approach has already been established, with crizotinib 
receiving accelerated approval within 4 years following demonstration of considerable efficacy in a 
targeted (ALK+) population [86]. Nevertheless, involvement of networks such as ETOP may be 
needed so that trials can be undertaken in selected populations due to the number of patients 
required for screening. New surrogate endpoints (e.g. quality of life or PFS) are also needed for 
future trials due to the difficulty in demonstrating survival benefit. 
Adjuvant platinum-based chemotherapy improves survival in completely resected early-stage NSCLC 
and is now standard treatment in this setting based on the results of phase III trials [87–90].
Nevertheless, the impact is limited and predictive markers are needed in order to better select the 
patients most likely to benefit from adjuvant treatment. Indeed, the value of this strategy has 
already been demonstrated in the IALT trial in which adjuvant cisplatin-based chemotherapy 
significantly prolonged survival among patients with completely resected NSCLC and ERCC1-negative 
tumours (hazard ratio [HR] 0.65; p=0.002), whereas no benefit was seen in ERCC1-postive patients 
(HR 1.14; p=0.40) [88]. Recently, however, this finding has been called into question due to the 
inability of currently available ERCC1 antibodies to detect the unique functional ERCC1 isoform [59].
Consequently, the usefulness of ERCC1 expression in guiding treatment for NSCLC patients is limited 
at present. Nevertheless, the results of several ongoing studies investigating tailored adjuvant 
therapy based on expression of other markers (e.g. EGFR mutations and thymidylate synthase) are 
eagerly awaited. Additionally, use of immunotherapy in the adjuvant setting is being evaluated in 
the MAGRIT (MAGE-A3 as Adjuvant, Non-Small Cell Lung Cancer Immunotherapy) trial. Gaining a 
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better understanding of the biology of targeted agents and obtaining long-term toxicity data before 
investigation in the adjuvant setting is also likely to improve the success of adjuvant trials. 
Summary 
Advances have been made in NSCLC management over the last three decades leading to small 
increases in 5-year survival rates across Europe (2–7%) [91–94], though further improvements are 
needed. However, advances in understanding of the molecular biology of the disease will help in the 
identification of novel targeted agents and development of personalised strategies for the numerous 
small subsets of defined NSCLC, with progress in imaging and treatment delivery also likely to 
improve outcomes. Furthermore, it is hoped that implementation of some of the strategies 
identified in this article will go some way to improving the outlook for patients with NSCLC.
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Figure legend
Figure 1. Mechanisms of tyrosine kinase inhibitor-acquired resistance. Reproduced with permission 
from Lovly & Pao, 2012 [59].
ALK, anaplastic lymphoma kinase; pEGFR, phosphorylated epidermal growth factor receptor.
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Table 1
Adenocarcinoma classification proposed by the IASLC/ATS/ERS. Reproduced with permission from 
Travis et al., 2011 [7].
! ! Preinvasive lesions
o Atypical adenomatous hyperplasia
o Adenocarcinoma in situ (≤3 cm [formerly BAC])
 Non-mucinous
 Mucinous
 Mixed mucinous/non-mucinous
! ! Minimally invasive adenocarcinoma (≤3 cm lepidic predominant tumour with ≤5 mm invasion
o Non-mucinous
o Mucinous
o Mixed mucinous/non-mucinous
! ! Invasive adenocarcinoma
o Lepidic predominant (formerly non-mucinous BAC pattern, with >5 mm invasion)
o Acinar predominant
o Papillary predominant
o Micropapillary predominant
o Solid predominant with mucin production
! ! Variants of invasive carcinoma
o Invasive mucinous adenocarcinoma (formerly mucinous BAC)
o Colloid
o Foetal (low and high grade)
o Enteric
ATS, American Thoracic Society; BAC, bronchioloalveolar carcinoma; ERS, European Respiratory Society; IASLC, 
International Association for the Study of Lung Cancer.
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Table 2
Novel targets for drug treatment in non-small cell lung cancer and agents in development.
Target Agent Company Phase of development
EGFR GA201 Roche I
HER2 Afatinib (BIBW2992)
PF-00299804
Boehringer Ingelheim
Pfizer
III
II
HER3 MM-121
U3-1287 (AMG888)
Merrimack Pharmaceuticals
U3 Pharma/Amgen
I/II
I/II
IGF-1R Figitumumab (CP-751,871)
OSI-906
R1507
Cixutumumab (IMC-A12)
AMG-479
XL-228
Pfizer
OSI Pharmaceuticals/Astellas
Roche
ImClone Systems
Amgen
Exelixis
III
II
II
I/II
I/II
I
HGF AMG102 Amgen II
MET MetMAb
XL880
Cabozantinib (XL184)
ARQ-197
Roche
Exelixis
Exelixis
ArQule
II
II
II
I
PI3K XL-147
GDC-0941
Exelixis/Sanofi
Genentech
I
I
PI3K/mTOR XL-765 Exelexis/Sanofi I
AKT MK-2206 Merck I
PARP-1 Iniparib
Veliparib 
Olaparib
BiPar/Sanofi Aventis
Abbot 
AstraZeneca
II/IIIII
I/II
TRAIL Mapatumumab
Conatumumab
CS-1008
PRO95780
AMG655
GSK
Amgen
Daiichi Sankyo
Genentech
Amgen
II
II
II
II
I/II
Hsp90 Ganetespib (STA-9090)
IPI-504
Synta Pharmaceuticals
Infinity
II/III
II
CDK PD0332991
Seliciclib (CYC202)
Pfizer
Cyclacel
II
II
HDAC Vorinostat Pantheon II
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CDK, cyclin dependent kinase; EGFR, epidermal growth factor receptor; HDAC, histone deacetylase; HER2, human 
epidermal growth factor receptor 2; HER3, human epidermal growth factor receptor 3; HGF, hepatocyte growth factor; 
Hsp90, heat-shock protein 90; IGF-1R, insulin-like growth factor 1 receptor; mTOR, mammalian target of rapamycin; PARP-
1, poly(ADP-ribose)polymerase-1; PI3K, phosphatidylinositol 3-kinase; TRAIL, tumour necrosis factor-related apoptosis-
inducing ligand.
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Table 3
Challenges in NSCLC and suggestions for addressing them.
Challenge Proposal for addressing
Healthcare policies, medical approaches 
and funding vary across Europe, limiting 
advances in oncology healthcare 
provision 
! ! Oncology platforms (e.g. EORTC, ESMO, ETOP, 
EurocarePlatform, IASLC) to co-ordinate collaboration 
between healthcare professionals and industry to 
improve outcomes
Incidence of lung cancer varies 
considerably between countries in 
Europe 
! ! Collaboration between countries and centres though 
ETOP and other oncology platforms
! ! Improvements in patient education
! ! Implementation of free screening and smoking 
cessation programmes
! ! Use of customised therapies to improve outcomes
! ! Identification of enriched populations to improve 
clinical trial success
Quality of care differs between centres ! ! Concentration of healthcare provision in specialist 
centres
Mortality rates from lung cancer have 
remained largely unchanged over the 
past 30 years 
! ! Development of new treatment strategies 
! ! Implementation of strategies aimed at earlier 
diagnosis 
Progress in drug development in NSCLC 
has been slow and the results of many 
Phase III trials of targeted agents over 
the past decade have been negative
! ! Identification of predictive biomarkers of response
! ! Recruitment of patients on the basis of tumour 
biology
! ! Involvement of oncology platforms such as ETOP to 
co-ordinate screening
! ! Use of a combination of targeted agents to avoid 
cross-stimulation of signalling pathways
Survival benefits are difficult to 
demonstrate in clinical trials 
! ! Development of surrogate endpoints (e.g. PFS, 
quality of life)
The benefit of adjuvant trials in NSCLC is 
unclear
! ! Improvement in identification of the patients most 
likely to benefit from adjuvant therapy
! ! Obtain better understanding of the biology of 
targeted agents before investigation in the adjuvant 
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setting
! ! Obtain long-term toxicity data on novel agents before 
undertaking adjuvant trials
The subpopulations who will benefit 
from particular targeted therapies is 
uncertain
! ! Identification of predictive biomarkers of response
Intellectual property rights can be a 
barrier to the clinical use of biomarkers 
and may limit drug development for 
rare mutations
! ! Development of inexpensive biomarker assays in 
parallel with drug development 
! ! Collaboration between centres to avoid use of 
multiple detection methods, improve reproducibility 
and avert false positives
The quality and availability of tissue 
samples may be a challenge for the 
future due to routine testing for 
increasing numbers of mutations 
! ! Centralise molecular diagnostics across the oncology 
community to reduce costs and improve quality 
control 
Treatment for stage III NSCLC is 
challenging due to patient comorbidity 
and tumour heterogeneity 
! ! Development of novel treatment approaches 
including immunomodulatory strategies, cell cycle 
agents and novel cytostatics
! ! Use of ‘window of opportunity’ trials to test new 
agents or strategies 
Resistance to TKIs develops in almost all 
patients and the optimum treatment for 
progression after TKI treatment is 
unclear 
! ! Prospective studies investigating the benefit of 
continuation of TKI treatment beyond progression
! ! Combination of targeted agents or addition of a 
cytotoxic agent to a targeted agent to delay/prevent 
resistance
EORTC, European Organisation for R search and Treatment of Cancer; ESMO, European Society for Medical Oncology; 
ETOP, European Thoracic Oncology Platform; IASLC, International Association for the Study of Lung Cancer NSCLC, non-
small cell lung cancer; PFS, progression-free survival; TKI, tyrosine kinase inhibitor.
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